( VANCOUVER April 17 2007 /PRNewswire/...)OncoGenex Technologies Announces Phase II Data of OGX-011 in,Metastatic Breast Cancer at American Association for Cancer,Research 2007 Annual Meeting,Health

VANCOUVER, April 17, 2007 /PRNewswire/ - OncoGenex Technologies Inc. announced today data from a Phase II clinical trial of OGX-011 in combination with docetaxel in patients with metastatic breast cancer (MBC). Data was presented by the National Cancer Institute of Canada - Clinical Trials Group at the American Association for Cancer Research 2007 Annual Meeting in Los Angeles, Calif.

    Investigators concluded:

        -  Of the 15 patients treated, five patients (33.3 percent) showed a

           partial response and nine patients (60 percent) showed disease

           stabilization

        -  Of the nine patients reported with stable disease, tumor reduction

           ranged from approximately eight to 28 percent and disease

           stabilization was sustained for a median of 9.3 months

        -  Only one patient advanced to progressive disease

        -  While patient monitoring is ongoing, the median progression free

           survival for all patients was eight months and the median time for

           survival has not yet been reached

        -  Clinical activity was seen for the combination of OGX-011 and

           docetaxel in this generally pre-treated group of patients with

           MBC, but did not meet the pre-determined criteria of six or more

           patients achieving tumour size reductions exceeding 30 percent

           required to expand the trial into a second stage of accrual

        -  Serum clusterin levels fell on treatment in most patients, and

           there was no statistical correlation between changes from baseline

           in clusterin levels and objective tumor response

"Taxanes represent an active class of chemotherapeutic agents currently used in the treatment of breast cancer, however the majority of patients will eventually develop resistance to the therapies," said Dr. Stephen Chia, Principal Investigator for this study
'"/>